EVITA试验:维生素K1乳膏预防西妥昔单抗所致皮肤毒性的双盲随机II期研究
EVITA是一项双盲、溶媒对照、随机II期试验,评估维生素K1乳膏联合多西环素对比多西环素联合溶媒预防西妥昔单抗所致皮肤毒性的效果。研究纳入126例接受一线西妥昔单抗+FOLFIRI的转移性结直肠癌患者,主要终点为8周内≥2级皮疹发生率,两组无显著差异。但维生素K1乳膏组从第5周起WoMo评分中皮疹严重程度和裂隙更少,生活质量、疗效和依从性两组相当。
要点
- 维生素K1乳膏未降低≥2级皮疹发生率(主要终点未达到)。
- 从第5周起,维生素K1乳膏组WoMo评分示皮疹严重程度和裂隙减少。
- 两组生活质量、疗效及依从性相当,维生素K1乳膏耐受性良好。
核心结论
- 维生素K1乳膏联合多西环素未能显著降低西妥昔单抗所致≥2级皮疹的发生率。
- 但维生素K1乳膏可减轻痤疮样皮疹的严重程度(依据WoMo评分),尤其从第5周起。
研究设计与样本
- 双盲、溶媒对照、随机II期试验。
- 纳入126例接受一线西妥昔单抗+FOLFIRI治疗的转移性结直肠癌患者。
- 随机分为多西环素+维生素K1乳膏组或多西环素+溶媒组。
- 主要终点为8周皮肤治疗期间≥2级皮疹发生率(NCI CTCAE v4.02),研究有80%把握度显示≥2级皮疹发生率降低20%。
主要发现
- 两组≥2级皮疹发生率相当。
- WoMo评分中皮肤受累百分比无差异。
- 从第5周起,维生素K1乳膏组皮疹严重程度和裂隙更少。
- 两组生活质量和疗效及依从性相当。
关键数值与推荐
- 主要终点≥2级皮疹发生率两组无显著差异。
- WoMo评分显示维生素K1乳膏组从第5周起皮疹严重程度和裂隙减少。
- 生活质量、疗效和依从性两组相当。
临床怎么用
- 维生素K1乳膏可作为预防性治疗的一部分,用于减轻西妥昔单抗所致痤疮样皮疹的严重程度。
- 维生素K1乳膏未显示降低≥2级皮疹发生率,不应替代标准预防措施。
局限性
- 主要终点未达到,维生素K1乳膏对≥2级皮疹发生率无显著影响。
- 研究为II期试验,样本量有限(126例),需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acne-like skin rash is a frequently occurring adverse event associated with drugs against the epidermal growth factor receptor. This randomized vehicle-controlled study investigated the addition of vitamin K1 cream to doxycycline in patients with metastatic colorectal cancer treated with cetuximab. PATIENTS AND METHODS: Patients receiving first-line cetuximab + FOLFIRI were randomly assigned to prophylactic treatment with doxycylin and vitamin K1 cream or doxycycline and the vehicle. The primary end point of the study was the incidence of grade ≥ 2 skin rash (NCI CTCAE version 4.02) during 8 weeks of skin treatment. Secondary end points comprised skin rash according to a more thorough tripartite skin toxicity score (WoMo), quality of life, efficacy, and compliance. The study had 80% power to show a 20% reduction of the incidence of grade ≥ 2 skin rash. RESULTS: A total of 126 patients were analyzed. The incidence of skin rash grade ≥ 2 was comparable between the arms. Likewise, no difference was seen in the WoMo score with respect to the percentage of skin affected. However, starting in week 5 and increasing over time patients treated with vitamin K1 cream had less severe rash and fewer fissures. Quality of life as well as efficacy and compliance with study medication and anticancer treatment was comparable in both arms. CONCLUSION: The primary end point of decreasing grade ≥ 2 skin rash was not met. However, using vitamin K1 cream as part of prophylactic treatment decreased the severity of acne-like skin rash according to WoMo, an alternative and more thorough skin toxicity scoring tool.
引用
- Hofheinz RD, Lorenzen S, Trojan J, et al. EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. Ann Oncol. 2018. PMID: 29360920. doi:10.1093/annonc/mdy015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。